NCT05668884View on ClinicalTrials.gov

GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

October 18, 2022

Primary Completion Date

September 30, 2026

Study Completion Date

March 31, 2027

Conditions
Biliary Tract Carcinoma
Interventions
COMBINATION_PRODUCT

Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab

Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab every 3 weeks

Trial Locations (1)

200062

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER